JP6267190B2 - 悪液質の予防用または治療用組成物 - Google Patents

悪液質の予防用または治療用組成物 Download PDF

Info

Publication number
JP6267190B2
JP6267190B2 JP2015511378A JP2015511378A JP6267190B2 JP 6267190 B2 JP6267190 B2 JP 6267190B2 JP 2015511378 A JP2015511378 A JP 2015511378A JP 2015511378 A JP2015511378 A JP 2015511378A JP 6267190 B2 JP6267190 B2 JP 6267190B2
Authority
JP
Japan
Prior art keywords
composition
cachexia
peptide
preventing
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015511378A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517489A (ja
JP2015517489A5 (enExample
Inventor
サン チェ キム
サン チェ キム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2015517489A publication Critical patent/JP2015517489A/ja
Publication of JP2015517489A5 publication Critical patent/JP2015517489A5/ja
Application granted granted Critical
Publication of JP6267190B2 publication Critical patent/JP6267190B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
JP2015511378A 2012-05-11 2013-05-10 悪液質の予防用または治療用組成物 Active JP6267190B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
KR10-2012-0050533 2012-05-11
KR10-2012-0050529 2012-05-11
KR20120050529 2012-05-11
KR20120050533 2012-05-11
KR20120071989 2012-07-02
KR10-2012-0071989 2012-07-02
KR10-2012-0104207 2012-09-19
KR20120104207 2012-09-19
PCT/KR2013/004176 WO2013169077A1 (ko) 2012-05-11 2013-05-10 악액질 예방 또는 치료용 조성물

Publications (3)

Publication Number Publication Date
JP2015517489A JP2015517489A (ja) 2015-06-22
JP2015517489A5 JP2015517489A5 (enExample) 2016-06-30
JP6267190B2 true JP6267190B2 (ja) 2018-01-24

Family

ID=49551008

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015511378A Active JP6267190B2 (ja) 2012-05-11 2013-05-10 悪液質の予防用または治療用組成物
JP2015511371A Active JP6262721B2 (ja) 2012-05-11 2013-05-10 敗血症の予防用または治療用の組成物
JP2015511374A Active JP6262722B2 (ja) 2012-05-11 2013-05-10 関節リウマチの予防用または治療用組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015511371A Active JP6262721B2 (ja) 2012-05-11 2013-05-10 敗血症の予防用または治療用の組成物
JP2015511374A Active JP6262722B2 (ja) 2012-05-11 2013-05-10 関節リウマチの予防用または治療用組成物

Country Status (6)

Country Link
US (3) US9730984B2 (enExample)
EP (3) EP2875824B1 (enExample)
JP (3) JP6267190B2 (enExample)
KR (3) KR101997757B1 (enExample)
CN (3) CN104507489B (enExample)
WO (3) WO2013169060A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022001591A (ja) * 2012-05-11 2022-01-06 ジェムバックス アンド カエル カンパニー，リミティド 抗炎症活性を有するペプチド、及びそれを含む組成物

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6267190B2 (ja) 2012-05-11 2018-01-24 ジェムバックス アンド カエル カンパニー，リミティド 悪液質の予防用または治療用組成物
US10967000B2 (en) 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
WO2014171792A1 (ko) 2013-04-19 2014-10-23 주식회사 카엘젬백스 허혈성 손상 치료 및 예방용 조성물
EP4063863A1 (en) 2013-06-07 2022-09-28 Gemvax & Kael Co., Ltd. Gv1001, gemcitabine and capecitabine for use in the treatment of pancreatic cancer in high eotaxin baseline level patients
ES2808076T3 (es) * 2013-06-21 2021-02-25 Gemvax & Kael Co Ltd Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso
CN105899224B (zh) 2013-10-23 2019-12-13 珍白斯凯尔有限公司 用于治疗和预防良性前列腺增生的组合物
CN105848667B (zh) 2013-11-22 2020-05-19 珍白斯凯尔有限公司 具有血管生成抑制活性的肽和包含所述肽的组合物
CN105939723B (zh) 2013-12-17 2020-02-28 珍白斯凯尔有限公司 前列腺癌治疗用组合物
US9937240B2 (en) 2014-04-11 2018-04-10 Gemvax & Kael Co., Ltd. Peptide having fibrosis inhibitory activity and composition containing same
ES2962532T3 (es) 2014-04-30 2024-03-19 Gemvax & Kael Co Ltd Composición para el trasplante de órganos, tejidos o células, kit y procedimiento de trasplante
ES2936383T3 (es) * 2014-08-08 2023-03-16 Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio Terapias basadas en transcriptasa inversa de la telomerasa para el tratamiento de afecciones asociadas con el infarto de miocardio
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
US10835582B2 (en) 2015-02-27 2020-11-17 Gemvax & Kael Co. Ltd. Peptide for preventing hearing loss, and composition comprising same
ES2886946T3 (es) 2015-07-02 2021-12-21 Gemvax & Kael Co Ltd Péptido con efecto antiviral y composición que lo contiene
EP3372613A4 (en) * 2015-11-03 2019-07-10 Gemvax & Kael Co., Ltd. PEPTIDE WITH NERVE DAMAGE PREVENTION AND REGENERATION EFFECT AND COMPOSITION THEREOF
KR101897121B1 (ko) * 2016-03-09 2018-09-10 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
US10898540B2 (en) 2016-04-07 2021-01-26 Gem Vax & KAEL Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
KR20200001730A (ko) * 2018-06-28 2020-01-07 차의과학대학교 산학협력단 김치를 포함하는 악액질 예방, 개선 또는 치료용 조성물
KR102276941B1 (ko) * 2018-07-03 2021-07-14 서울대학교산학협력단 류마티스 관절염 치료용 펩티드 및 그의 용도
EP4125863A1 (en) * 2020-04-03 2023-02-08 Medsenic Use of an arsenic compound for treating a short or long cytokine storm in various autoimmune/inflammatory diseases in humans or animals
KR102486196B1 (ko) * 2020-04-09 2023-01-06 대진대학교 산학협력단 무당벌레 유충 유래 펩타이드를 유효성분으로 포함하는 패혈증의 예방 또는 치료용 약제학적 조성물
KR20250025783A (ko) * 2023-08-14 2025-02-25 건국대학교 산학협력단 양배추은무늬밤나방 유충으로부터 분리된 세크로핀 펩타이드 및 그의 패혈증, 박테리아 감염증, 또는 염증성 질환의 치료 용도
KR20250145172A (ko) 2024-03-28 2025-10-13 한림대학교 산학협력단 암 악액질의 예방 또는 치료를 위한 약학 조성물

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000515523A (ja) 1996-07-22 2000-11-21 ザ・ビクトリア・ユニバーシティ・オブ・マンチェスター 創傷および線維性障害の治療における性ステロイド機能モジュレーターの使用
US6610839B1 (en) * 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
ES2205132T5 (es) * 1996-10-01 2012-06-18 Geron Corporation Subunidad catalítica de la telomerasa humana
DE69837707T2 (de) 1997-05-15 2008-01-10 Chugai Seiyaku K.K. Heilmittel für kachexie
CN1270634A (zh) 1997-07-01 2000-10-18 卡姆比亚生物系统有限责任公司 脊椎动物端粒酶基因和蛋白质及其用途
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
IL132406A0 (en) 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
US6815426B2 (en) 2001-02-16 2004-11-09 E. I. Du Pont De Nemours And Company Angiogenesis-inhibitory tripeptides, compositions and their methods of use
US6622663B2 (en) 2001-03-27 2003-09-23 Exxonmobil Research And Engineering Company Fuel composition supply means for driving cycle conditions in spark ignition engines
US6967211B2 (en) 2001-04-10 2005-11-22 Nippon Shinyaku Co. Ltd. Remedial agent for chronic articular rheumatism
MXPA03010575A (es) 2001-05-16 2005-03-07 Yeda Res & Dev Uso de inhibidores de il-08 para el tratamiento o prevencion de sepsis.
AU2002363231A1 (en) 2001-10-29 2003-05-12 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
RS89204A (sr) 2002-04-10 2006-12-15 Applied Research Systems Ars Holding N.V. Upotreba osteoprotegerina za lečenje i/ili prevenciju fibrozne bolesti
KR20050020987A (ko) 2002-06-12 2005-03-04 바이오겐 아이덱 엠에이 인코포레이티드 아데노신 수용체 길항제를 사용하여 허혈 재관류 손상을치료하는 방법
KR20050040517A (ko) 2003-10-29 2005-05-03 주식회사 오리엔트 허혈성 질환에 대한 저항성을 나타내는 형질전환 생쥐
EP1530965B1 (en) 2003-11-11 2006-03-08 Mattern, Udo Controlled release delivery system of sexual hormones for nasal application
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
JP5273721B2 (ja) 2005-03-21 2013-08-28 ビカス セラピューティクス，エルエルシー 悪液質を緩和するための組成物および方法
TW200803894A (en) 2005-11-25 2008-01-16 Univ Keio Prostate cancer therapeutic agents
EP1968643A2 (en) 2005-12-16 2008-09-17 Diatos Cell penetrating peptide conjugates for delivering of nucleic acids into a cell
KR100859972B1 (ko) 2006-02-20 2008-09-25 이화여자대학교 산학협력단 막투과 단백질 도메인 펩타이드
JP2009544688A (ja) 2006-07-24 2009-12-17 フォーヒューマンテック カンパニー リミテッド 虚血性疾患の緩和及び治療のための医薬組成物並びにそれを伝達するための方法
EP2837636B1 (en) 2007-01-29 2018-04-11 Procell Therapeutics Inc. Novel macromolecule transduction domains and methods for identification and uses thereof
EP2637020A3 (en) 2007-06-29 2014-01-08 Correlogic Systems Inc. Predictive markers for ovarian cancer
CN103298935A (zh) 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
WO2009054996A2 (en) 2007-10-25 2009-04-30 Genelux Corporation Systems and methods for viral therapy
GB2455539B (en) 2007-12-12 2012-01-18 Cambridge Entpr Ltd Anti-inflammatory compositions and combinations
ES2602453T3 (es) 2008-06-16 2017-02-21 Mediolanum Farmaceutici S.P.A. Inmunoterapia antitumoral
KR101414854B1 (ko) 2008-07-08 2014-07-03 엘지전자 주식회사 디지털 텔레비전 및 디지털 텔레비전 시스템
ES2334315B1 (es) 2008-07-29 2011-02-28 Universitat Pompeu Fabra Peptidos con capacidad de penetracion celular y sus usos.
US20110183925A1 (en) 2008-09-22 2011-07-28 Nisshin Pharma Inc. Anti-inflammatory peptide
KR101169030B1 (ko) 2009-01-21 2012-07-26 애니젠 주식회사 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
KR101783291B1 (ko) 2009-05-20 2017-09-29 도레이 카부시키가이샤 세포막 투과성 펩티드
KR20110057049A (ko) 2009-11-23 2011-05-31 박의신 기능성 전립선염 치료제
KR20110062943A (ko) 2009-12-04 2011-06-10 주식회사종근당 퀴나졸린 유도체를 유효성분으로 하는 전립선 비대증 예방 또는 치료제
CA2786535C (en) 2010-01-11 2019-03-26 Curna, Inc. Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
JP6042211B2 (ja) 2010-02-16 2016-12-14 ウルティモバックス エーエス ポリペプチド
FR2960542B1 (fr) 2010-05-27 2012-08-17 Esther Suzy Arlette Fellous Peptide en tant que medicament, en particulier pour le traitement du cancer
KR101263212B1 (ko) 2010-05-28 2013-05-10 성신여자대학교 산학협력단 신규한 세포막 투과성 펩타이드 및 그의 용도
WO2011150494A1 (en) 2010-05-30 2011-12-08 The Governing Council Of The University Of Toronto Mitochondrial penetrating peptides as carriers for anticancer compounds
KR101348284B1 (ko) 2010-09-09 2014-01-03 주식회사 나이벡 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR20120121196A (ko) 2011-04-26 2012-11-05 주식회사 글루칸 관절염 치료제
KR101284772B1 (ko) 2011-05-24 2013-07-17 정종문 항염증, 진통효과를 가지는 기능성 식품 조성물
KR20120133661A (ko) 2011-05-31 2012-12-11 주식회사 바이오포트코리아 아스타잔틴을 포함하는 항염증제
KR101361445B1 (ko) 2011-12-26 2014-02-12 성균관대학교산학협력단 펩타이드, 5-플루오로우라실, 및 성숙수지상세포를 포함하는 암 치료용 약학적 조성물
US9303247B2 (en) 2012-02-10 2016-04-05 Hakushinkouseikai Foundation Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine
WO2013135266A1 (en) 2012-03-12 2013-09-19 Gemvax As Treatment of non-small cell lung carcinoma by active immunotherapy
JP6267190B2 (ja) 2012-05-11 2018-01-24 ジェムバックス アンド カエル カンパニー，リミティド 悪液質の予防用または治療用組成物
CN108949717B (zh) * 2012-05-11 2023-06-20 珍白斯凯尔有限公司 抗炎性肽及包含其的组合物
US10967000B2 (en) 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
US9902945B2 (en) 2012-09-19 2018-02-27 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
WO2014046490A1 (ko) 2012-09-19 2014-03-27 주식회사 카엘젬백스 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
JP6510410B2 (ja) 2012-09-19 2019-05-08 ジェムバックス アンド カエル カンパニー，リミティド 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
WO2014171792A1 (ko) 2013-04-19 2014-10-23 주식회사 카엘젬백스 허혈성 손상 치료 및 예방용 조성물
EP4063863A1 (en) 2013-06-07 2022-09-28 Gemvax & Kael Co., Ltd. Gv1001, gemcitabine and capecitabine for use in the treatment of pancreatic cancer in high eotaxin baseline level patients
ES2808076T3 (es) 2013-06-21 2021-02-25 Gemvax & Kael Co Ltd Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso
CN105899224B (zh) 2013-10-23 2019-12-13 珍白斯凯尔有限公司 用于治疗和预防良性前列腺增生的组合物
CN105848667B (zh) 2013-11-22 2020-05-19 珍白斯凯尔有限公司 具有血管生成抑制活性的肽和包含所述肽的组合物
CN105939723B (zh) 2013-12-17 2020-02-28 珍白斯凯尔有限公司 前列腺癌治疗用组合物
US9937240B2 (en) 2014-04-11 2018-04-10 Gemvax & Kael Co., Ltd. Peptide having fibrosis inhibitory activity and composition containing same
ES2962532T3 (es) 2014-04-30 2024-03-19 Gemvax & Kael Co Ltd Composición para el trasplante de órganos, tejidos o células, kit y procedimiento de trasplante

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022001591A (ja) * 2012-05-11 2022-01-06 ジェムバックス アンド カエル カンパニー，リミティド 抗炎症活性を有するペプチド、及びそれを含む組成物
JP7449909B2 (ja) 2012-05-11 2024-03-14 ジェムバックス アンド カエル カンパニー，リミティド 抗炎症活性を有するペプチド、及びそれを含む組成物
JP2024052952A (ja) * 2012-05-11 2024-04-12 ジェムバックス アンド カエル カンパニー，リミティド 抗炎症活性を有するペプチド、及びそれを含む組成物
JP7757448B2 (ja) 2012-05-11 2025-10-21 ジェムバックス アンド カエル カンパニー，リミティド 抗炎症活性を有するペプチド、及びそれを含む組成物

Also Published As

Publication number Publication date
KR101997756B1 (ko) 2019-07-08
JP2015517489A (ja) 2015-06-22
US20160008438A1 (en) 2016-01-14
EP2875825A4 (en) 2016-03-23
KR20150022799A (ko) 2015-03-04
US9907837B2 (en) 2018-03-06
EP2875826B1 (en) 2017-08-23
EP2875826A1 (en) 2015-05-27
CN104507489B (zh) 2016-07-13
KR101997757B1 (ko) 2019-07-08
US9730984B2 (en) 2017-08-15
KR20150022798A (ko) 2015-03-04
EP2875824A1 (en) 2015-05-27
JP2015517488A (ja) 2015-06-22
US20150175978A1 (en) 2015-06-25
EP2875825B1 (en) 2017-12-13
KR101873773B1 (ko) 2018-08-02
JP2015518818A (ja) 2015-07-06
KR20150022800A (ko) 2015-03-04
EP2875824A4 (en) 2016-03-23
JP6262721B2 (ja) 2018-01-17
EP2875826A4 (en) 2016-03-23
CN104487081B (zh) 2017-12-12
CN104661672A (zh) 2015-05-27
CN104661672B (zh) 2017-03-08
WO2013169077A1 (ko) 2013-11-14
WO2013169067A1 (ko) 2013-11-14
EP2875825A1 (en) 2015-05-27
US9844584B2 (en) 2017-12-19
US20150353903A1 (en) 2015-12-10
JP6262722B2 (ja) 2018-01-17
CN104507489A (zh) 2015-04-08
EP2875824B1 (en) 2018-01-03
WO2013169060A1 (ko) 2013-11-14
CN104487081A (zh) 2015-04-01

Similar Documents

Publication Publication Date Title
JP6267190B2 (ja) 悪液質の予防用または治療用組成物
JP6788062B2 (ja) 抗炎症活性を有するペプチド、及びそれを含む組成物
JP7007333B2 (ja) 抗炎症活性を有するペプチド、及びそれを含む組成物
EP3130345B1 (en) Peptide having fibrosis inhibitory activity and composition containing same
KR20140104288A (ko) Tnf-알파 저해제
KR20160086864A (ko) 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
JP5982394B2 (ja) ＭＭＰ基質で連結したβｉｇ−ｈ３断片ペプチド及びそのリウマチ性関節炎予防及び治療用途
CN121021662A (zh) 一种猪源irf5蛋白的抗原肽及其多克隆抗体、制备方法及应用
KR20140104287A (ko) Tnf-알파 저해제

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160510

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20170404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171221

R150 Certificate of patent or registration of utility model

Ref document number: 6267190

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250